ReviewPediatric transplantation2026
Holding On or Letting Go: Immunosuppression After Pediatric Kidney Allograft Failure.
Review in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Kidney allograft failure is a devastating event often marked by return to dialysis and is associated with increased morbidity and mortality. Given the young age at transplant for pediatric recipients, they are likely to require retransplantation during their lifetime. Optimal immunosuppression (IS) management in the setting of a failing allograft is crucial to preserve residual renal function, prevent graft intolerance, and limit the development of anti-HLA antibodies. The management of IS during allograft failure is highly variable between providers and reflects the paucity of data to guide clinical decision-making. In addition, pediatric recipients have shorter waiting times for kidney transplants due to priority allocation for deceased donors compared to adult candidates, suggesting that current protocols may not be generalizable to pediatric kidney recipients with allograft failure. In this review we summarize the extent of current recommendations, identify limitations as they pertain to pediatric patients, and provide recommendations for vitally needed future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.